Rigor Reviewed

Rigor-Reviewed Manuscript

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.

Name: Αlpha¹ Rigor Record — Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
Item: Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
Rating: 59
Author: Αlpha¹

Long GV, Carlino MS, Au-Yeung G, Spillane AJ, Shannon KF, Gyorki DE, Hsiao E, Kapoor R, Thompson JR, Batula I, Howle J, Ch'ng S, Gonzalez M, Saw RPM, Pennington TE, Lo SN, Scolyer RA, Menzies AM

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2★ (Weak), 0 critical, 5 high issues for “Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×18−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced6 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted randomized phase 2 trial with strong scientific premise, rigorous design, and transparent reporting. The main weaknesses are a vague data availability statement, lack of explicit reporting guideline adherence, and a concerning rate of statistical inconsistencies flagged by automated verification.

Both reviewers agreed on study type (interventional) and on all dimension statuses except statistical analysis, where the deterministic verification provided additional evidence that led to a downgrade from pass to warn. The statistics verification covered only a subset of tests (those with test statistics + df or effect estimates + CI); threshold-only p-values and exact tests were not machine-verifiable. The copyedit pass flagged minor internal inconsistencies in Table 3 and a typo in the funding acknowledgement.

3 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks. 18 printed percentages that do not match their own count.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple studies (Keynote-022, COMBI-i, IMspire150, SECOMBIT, DREAMseq, SWOG S1801) and discusses the mechanisms by which targeted therapy may enhance immunotherapy. It also acknowledges limitations of prior work, such as the lack of benefit of neoadjuvant targeted therapy alone and the need for better combinations. The hypothesis follows logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on BRAF/MEK inhibitors and immune checkpoint inhibitors, and provides a logical rationale for combining them in the neoadjuvant setting.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Three trials (Keynote-022, COMBI-i and IMspire150) have tested the use of BRAF-targeted therapy with or without concurrent anti-PD-1 in advanced BRAF-mutant melanoma.”

paraphrase[Introduction, paragraph 2]

“Treatment with BRAF/MEK inhibitors has been shown to induce a favorable tumor immune microenvironment in melanoma.”

paraphrase[Introduction, paragraph 4]

“Interestingly, the 2-year recurrence-free survival (RFS) rate was only 79% in patients achieving a pCR to targeted therapy, compared with 96% for patients achieving any pathological response to an ICI regimen.”

PASSReviewer 2· 90% conf

Evidence

paraphrase[Introduction, paragraph 2]

“Three trials (Keynote-022, COMBI-i and IMspire150) have tested the use of BRAF-targeted therapy with or without concurrent anti-PD-1 in advanced BRAF-mutant melanoma.”

direct quote[Introduction, paragraph 1]

“Immune changes early during targeted therapy suggest the mechanisms of each drug class could work synergistically.”